Silver Book Fact

Treatment with bisphosphonates are highly cost-effective in women over the age of 70 with osteoporosis and a previous fracture.

Fleurence R, Iglesias C, Johnson J. The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis: A structured review of the literature. PharmacoEcon. 2007; 25(11): 913-33. http://www.ncbi.nlm.nih.gov/pubmed/17960951

Reference

Title
The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis: A structured review of the literature
Publication
PharmacoEcon
Publication Date
2007
Authors
Fleurence R, Iglesias C, Johnson J
Volume & Issue
Volume 25, Issue 11
Pages
913-33
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Reducing risk of fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to 10%.  
  • A study of a number of osteoporosis treatments found cost-effectiveness ratios as low as $55,000 per QALY.  
  • A meta-analysis of clinical trials found that calcium supplements reduced the risk of vertebral fractures by around 23%.  
  • Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.  
  • Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.